PsychoGenics careers

There are currently four proprietary platforms, SmartCube®, NeuroCube®, PhenoCube® and eCube™. Using these platforms PsychoGenics can screen tens of thousands of compounds for CNS activity and identify those with a behavioral/physiological profile that reverses a disease model phenotype or that are similar to drugs that treat a specific neuropsychiatric disorder. The company’s technologies are being applied to discover treatments for psychiatric, cognitive, neurodegenerative, and seizure disorders, and pain. We partner and provide services to biotech, pharma, and non-profit organizations interested in developing new treatments.